- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07717619
Antenatal High-Risk Pregnancy Intervention Bundle in Rural Nepal
15 de julio de 2026 actualizado por: University of California, San Francisco
Implementing and Evaluating an Antenatal High-Risk Pregnancy Intervention Bundle in Rural Nepal
The proposed study will assess and implement a comprehensive antenatal HRP screening and telehealth follow-up program in rural Nepal. The main questions it aims to answer are:
- To estimate the burden of HRPs using the existing Antenatal Risk-Score Checklist in rural Nepal
- Assess acceptability, feasibility, preliminary effectiveness, and implementation outcomes of the HRP bundle at the primary healthcare in Nepal
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Estimado)
100
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Archana Shrestha, PhD
- Número de teléfono: +9779801002245
- Correo electrónico: archana@kusms.edu.np
Copia de seguridad de contactos de estudio
- Nombre: Anju Ranjit, MD MPH
- Número de teléfono: 4153533400
- Correo electrónico: anju.ranjit@ucsf.edu
Ubicaciones de estudio
-
-
Bagmati
-
Melamchi, Bagmati, Nepal
- Melamchi Primary Health Care Center
-
Contacto:
- Umang Raut (Medical Superintendent)
- Número de teléfono: +977 9860923221
- Correo electrónico: melamchiphc@gmail.com
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- all pregnant women above who are receiving antenatal care at Melamchi Primary Health Care Center
Exclusion Criteria:
- life-threatening maternal or fetal conditions requiring immediate tertiary-level care
- unable to provide informed consent due to cognitive or language barriers
- do not have access to a mobile phone for telehealth consultations.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Standard of Care
Usual prenatal care, including on-site consultation and visits from health facility staff
|
|
|
Comparador activo: High Risk Pregnancy (HRP) Bundle Intervention Arm
The intervention arm would include 1. identification of high-risk pregnancy 2. Teleconsultation with expert consultant 3. weekly call with patient navigator 4. training of health care provider for HRP care, and 5. visits in the weekly prenatal telehealth clinic
|
The intervention would include 1. identification of high-risk pregnancy 2. Teleconsultation with expert consultant 3. weekly call with patient navigator 4. training of health care provider for HRP care, and 5. visits in the weekly prenatal telehealth clinic
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maternal Near Miss
Periodo de tiempo: up to 60 days postpartum
|
life-threatening complication during pregnancy, childbirth, or within 42 days postpartum, but survives with appropriate medical intervention (We will use WHO criteria)
|
up to 60 days postpartum
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Neonatal death
Periodo de tiempo: Up to 28 days after birth
|
Number of neonatal deaths, defined as death of a liveborn infant within the first 28 days of life
|
Up to 28 days after birth
|
|
Low Apgar Score at 5 Minutes
Periodo de tiempo: At 5 minutes after birth
|
Number of infants with an Apgar score less than 7 at 5 minutes after birth
|
At 5 minutes after birth
|
|
Neonatal Intensive Care Unit Admission
Periodo de tiempo: Up to 30 days after birth
|
Number of infants admitted to a neonatal intensive care unit
|
Up to 30 days after birth
|
|
Need for Mechanical Ventilation
Periodo de tiempo: up to 30 days after birth
|
Number of infants requiring mechanical ventilation
|
up to 30 days after birth
|
|
Neonatal Respiratory Distress Syndrome
Periodo de tiempo: Up to 30 days after birth
|
Number of infants diagnosed with respiratory distress syndrome
|
Up to 30 days after birth
|
|
Neonatal Hypoglycemia
Periodo de tiempo: Up to 48 hours after birth
|
Number of infants with hypoglycemia, defined as less than 45 mg/dl
|
Up to 48 hours after birth
|
|
Low Birth Weight
Periodo de tiempo: At birth
|
Number of infants with birth weight less than 2500 grams
|
At birth
|
|
Composite Adverse Neonatal Outcome
Periodo de tiempo: up to 30 days after birth
|
Number of infants with at least one of the following: neonatal death, Apgar score less than 7 at 5 minutes, NICU admission, need for mechanical ventilation, respiratory distress syndrome, hypoglycemia
|
up to 30 days after birth
|
|
Antenatal Risk Screening Rate
Periodo de tiempo: Up to 24 months
|
Proportion of pregnant women enrolled in the study who undergo antenatal risk screening using the Antenatal Risk-Score Checklist
|
Up to 24 months
|
|
Referral Rate
Periodo de tiempo: Up to 24 months
|
Percentage of pregnant women referred to higher levels of care based on risks identified through antenatal risk screening
|
Up to 24 months
|
|
Telehealth Consultation Utilization Rate
Periodo de tiempo: Up to 24 months
|
Proportion of pregnant women in the High Risk Pregnancy Bundle Intervention Arm who utilize at least 80% of their recommended telehealth consultations
|
Up to 24 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Acceptability of Intervention Measure (AIM) Score
Periodo de tiempo: up to 24 months
|
We will assess the acceptability of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Acceptability of Intervention Measure (AIM), administered at both the patient and provider level.
|
up to 24 months
|
|
Intervention Appropriateness Measure (IAM) Score
Periodo de tiempo: Up to 24 months
|
We will assess the appropriateness of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Intervention Appropriateness Measure (IAM), administered at both the patient and provider level.
|
Up to 24 months
|
|
Feasibility of Intervention Measure (FIM) Score
Periodo de tiempo: Up to 24 months
|
We will assess the feasibility of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Feasibility of Intervention Measure (FIM), administered at both the patient and provider level.
|
Up to 24 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Anju Ranjit, MD MPH, University of California, San Francisco
- Investigador principal: Archana Shrestha, Kathmandu University School of Medicine/Dhulikhel Hospital
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
1 de agosto de 2026
Finalización primaria (Estimado)
31 de julio de 2027
Finalización del estudio (Estimado)
31 de julio de 2028
Fechas de registro del estudio
Enviado por primera vez
25 de junio de 2026
Primero enviado que cumplió con los criterios de control de calidad
15 de julio de 2026
Publicado por primera vez (Actual)
21 de julio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
21 de julio de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
15 de julio de 2026
Última verificación
1 de julio de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 26-46873
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
De-identified individual participant data will be shared, including quantitative survey data on primary outcomes (maternal near-miss) and secondary outcomes (maternal mortality, composite neonatal outcomes, stillbirth rate, preterm delivery, implementation outcomes), socio-demographic and reproductive health data, and chronic health condition data.
Qualitative data (de-identified transcripts) from focus group discussions and in-depth interviews on implementation barriers and facilitators will also be shared.
Process tracking data (service utilization records, monthly reports) may be shared in aggregate form.
Personally identifiable information will be removed prior to sharing.
Data will be shared in standard formats (e.g., Stata) in accordance with ICPSR standards, accompanied by a codebook and questionnaire to support interpretation.
Marco de tiempo para compartir IPD
Individual participant data and supporting information will be available beginning at the time of publication of the associated study results.
Data will remain available indefinitely upon request following publication, with no specified end date.
Criterios de acceso compartido de IPD
De-identified data will be accessible to qualified researchers and program implementers who submit a formal data request and agree to comply with applicable ethical guidelines and data use terms.
Requestors will have access to de-identified quantitative datasets, qualitative transcripts, and associated metadata (questionnaire, codebook).
Potentially identifying variables will be classified under restricted access and made available only through a secure virtual data enclave (e.g., DSDR/ICPSR) for approved researchers.
Data will be archived on a secure server at Dhulikhel Hospital-Kathmandu University Hospital, with a backup at UCSF.
Requests will be reviewed by the study's Principal Investigators or designated project coordinator.
A Certificate of Confidentiality will safeguard participant information throughout the access process.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .